UKRI – BBSCR investments ‘likely critical’ to UK AMR vision, experts say
An expert panel has concluded that BBSRC’s investments are ‘likely to be critical’ in realising the UK’s 20-year vision for tackling antimicrobial resistance.
Antimicrobial resistance (AMR) poses a major threat to human health, contributing to almost 5 million deaths worldwide in 2019 alone.
Bioscience research and innovation has the potential to play a vital role in addressing this global threat.
As the UK’s major public funder of bioscience research, the Biotechnology and Biological Sciences Research Council (BBSRC) invests around £30 million each year in AMR research.
Read the full news report here. Published on the 18th of November 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (25 janvier 2023). UKRI – BBSCR investments ‘likely critical’ to UK AMR vision, experts say. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/o66t





